ICD-10 Coding for Myelodysplastic Syndrome(D46.0, D46.0A, D46.0B)

Comprehensive guide to ICD-10 coding for myelodysplastic syndrome, including specific codes, documentation requirements, and common pitfalls.

Also known as:
MDSPreleukemia
Related ICD-10 Code Ranges

Complete code families applicable to Myelodysplastic Syndrome

Code Comparison: When to Use Each Code

Compare key differences between these codes to ensure accurate selection

CodeDescription
D46.0Refractory anemia without ring sideroblasts, so stated
D46.1Refractory anemia with ring sideroblasts
D46.9Myelodysplastic syndrome, unspecified

Clinical Decision Support

Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.

Key Information

Essential facts and insights aboutMyelodysplastic Syndrome

Differential Codes

Alternative codes to consider when ruling out similar conditions

Refractory anemia with ring sideroblastsD46.1
Refractory anemia without ring sideroblastsD46.0

Documentation & Coding Risks

Avoid these common issues when documenting Myelodysplastic Syndrome.

Failure to document specific subtype of MDS.

Impact

Clinical: May lead to inappropriate treatment plans., Regulatory: Increases risk of audit and compliance issues., Financial: Potential for reduced reimbursement.

Mitigation

Educate clinicians on the importance of detailed documentation., Implement checklists for documentation requirements.

Using D46.9 when specific subtype is documented.

Impact

Reimbursement: May result in lower reimbursement rates., Compliance: Increases risk of audit due to lack of specificity., Data Quality: Reduces accuracy of clinical data.

Mitigation

Ensure documentation specifies the subtype of MDS for accurate coding.

Use of unspecified codes

Impact

High audit risk when using D46.9 without specific subtype documentation.

Mitigation

Encourage detailed documentation and use of specific codes.

Frequently Asked Questions